We have generated transgenic mice that harbor a 140 kb genomic fragment of the human BRCA1 locus (TgN´BRCA1 GEN ). We ®nd that the transgene directs appropriate expression of human BRCA1 transcripts in multiple mouse tissues, and that human BRCA1 protein is expressed and stabilized following exposure to DNA damage. Such mice are completely normal, with no overt signs of BRCA1 toxicity commonly observed when BRCA1 is expressed from heterologous promoters. Most importantly, however, the transgene rescues the otherwise lethal phenotype associated with the targeted hypomorphic allele (Brca1 
Introduction
Inherited mutations within BRCA1 account for 1 ± 4% of breast and 4 ± 5% of ovarian cancers (Biesecker, 1993; Whittemore et al., 1997) . BRCA1 kindreds have increased rates of other cancers as well, and carriers show lifetime cancer risks of 60 ± 80%. Carrier frequencies have been calculated at one in 800 in the US population, and the number is considerably higher in women of Ashkenazi Jewish descent (Struewing et al., 1997) . Most mutations lead to premature termination of the nascent protein, but model systems to study these mutations have been slow to develop.
Brca1-null mice succumb to embryonic lethality early in life (E6.5 ± 9) (Gowen et al., 1996; Hakem et al., 1997; Ludwig et al., 1997) , an eect which is at least partially dependent on Trp53 (p53) gene status (Cressman et al., 1999b; Hakem et al., 1997; Ludwig et al., 1997) . In keeping with the high rate of TP53 mutation in BRCA1-derived human cancers (Crook et al., 1998; Phillips et al., 1999) , mice with mutations in Brca1 develop tumors which show allelic loss of Trp53 , and bigenic mice with mutations in both Brca1 +/7 and Trp53 7/7 are speci®cally prone to the development of breast cancers (Cressman et al., 1999b; Xu et al., 1999) . Paradoxically, human cells that lack BRCA1 are very dicult to obtain and doubly mutant mouse cells grow poorly due to high rates of chromosomal loss associated with defective G2 checkpoint control . Mouse cells lacking functional Brca1 are also more sensitive to ionizing radiation and oxidative stress (Shen et al., 1998) . One surprising result was that virtually all tumor-derived cell lines appeared to produce some BRCA1 (Lane et al., 1995; Scully et al., 1997a; Wilson et al., 1997) . Thus, BRCA1 displays some features which are atypical for tumor suppressor genes and there remains a signi®cant need for informative and genetically tractable models of BRCA1 function.
To date, there have been no eective strategies to replace BRCA1 functionality in vivo. The process is complicated by cellular senescence or apoptosis in many cells engineered to overexpress the BRCA1 cDNA from heterologous promoters (Aprelikova et al., 1999; Shao et al., 1996; Wilson et al., 1997; Zhang et al., 1998) . Since mouse embryos de®cient in Brca1 die early in development, a straightforward assay of function is to analyse human BRCA1 gene replacement vectors for their ability to rescue Brca1-de®cient mouse embryos. To test this notion, we generated mice that carry a 140 kb fragment of the BRCA1 locus (TgN´BRCA1 GEN ) and ®nd the transgene rescues the otherwise lethal phenotype observed in the homozygous Brca1 7/7 mice. We isolated human BRCA1 protein from these lines and found a correlation between expression level and rescue. Furthermore, the protein was correctly translated and stabilized following exposure to DNA damage. From these results, it is apparent that signi®cant conservation of function exists between human and mouse genes. This is notable since the mature proteins are only 60% identical at the amino acid level (Lane et al., 1995) . These results provide strong evidence that hypotheses regarding human BRCA1 function can be evaluated in mice. Candidate BRCA1 replacement vectors can be tested for their ability to support embryonic or adult physiological processes, and more accurate models of human disease alleles can be studied. TgN´BRCA1 mice can be manipulated experimentally (hormones, drugs, etc.) and genetically without the confounding eects of genetic background or the ethical issues associated with manipulating genes in humans.
Results

Placement of a Brca
DexllSA allele into an FVB/N genetic background creates a line of syngeneic mice suitable for analysis of BRCA1 transgenes A hypomorphic allele of murine Brca1 (Brca1 DexllSA/129 ( Figure 1a) ) was generated through homologous recombination in embryonic stem (ES) cells derived from a 129
SvEv genetic background (C Deng and P Leder, unpublished). To remove issues of multiple genetic backgrounds from the analysis of BRCA1 transgenic mice, the Brca1
DexllSA mutation was backcrossed into FVB/N mice for 12 generations to produce a new line, Brca1
DexllSA /FVB . As described for various Brca1-null alleles made by gene targeting in 129 backgrounds (Gowen et al., 1996; Hakem et al., 1997; Liu et al., 1996; Ludwig et al., 1997; Shen et al., 1998) , the majority of Brca1
DexllSA /FVB homozygous (Brca1
) embryos die before embryonic day 9 and never produce viable ospring. Brca1
DexllSA /FVB heterozygotes (Brca1
) are normal and have no apparent predisposition to breast cancer. Attempts to identify normal transcripts in Brca1 7/7 embryos have failed, indicating that the mutation produces a null (or severely hypomorphic) allele of the Brca1 gene.
The wild-type human BRCA1 locus can be introduced into mice as a heritable transgene
In order to test the ability of human BRCA1 to rescue embryonic lethality in Brca1 7/7 embryos, we made repeated attempts to generate transgenic mice expressing full-length BRCA1 cDNAs under the control of heterologous promoters. The promoter-cDNA constructs included well-characterized promoters derived from the chick b-actin gene (n=80 embryos injected), cytomegalovirus (n=40), and the mouse mammary tumor virus (n=160). Pronuclear microinjection of these constructs resulted in very low yields of surviving founders, and none of these were shown to express human BRCA1 mRNA. These results provide evidence suggestive that mis-expression of BRCA1 has a phenotypic consequence (cellular arrest or lethality) that is not well tolerated during embryonic development.
To test whether genomic sequences from the human locus would mediate more appropriate expression in mice, we created transgenic mice carrying the entire human BRCA1 locus derived from PAC103014 (Brown et al., 1995) . The fragment contained all 25 exons of the BRCA1 gene (see Figure 1b) ; TgN´BRCA1 bigenic animals. The bigenic mice were subsequently mated and their ospring were analysed for Brca1 status. Viable Brca1 7/7 mice were recovered quantitatively from crosses with line B and, to a lesser extent, with line A (Figure 2 and Table 1 ). In Figure 2 , lanes 2, 6 and 12 represent 3-week-old Brca1 7/7 mice rescued by the presence of the BRCA1 transgene from line B. Subsequently, we established independent lines of Brca1
7/7
; TgN´BRCA1-B mice (maintained through the fourth generation). Such mice appear completely normal with respect to development, litter size, longevity and disease-free survival. Brca1 7/7 mice were never recovered in the absence of the human BRCA1 transgene (n4270) ( Table 1) or from crosses with lines C, D and E. Analyses of ospring from additional Brca1 +/7 matings provided evidence that a functional BRCA1 allele is absolutely required for embryonic development of animals with an otherwise wild-type genotype (n4400).
Studies of ospring from all Brca1
; TgN´BRCA1 lines demonstrated that TgN´BRCA1-B and TgN´BRCA1-A lines were both capable of directing rescue of Brca1 7/7 mice (Table 1) . Rescue by transgenic line A was signi®cantly less eective than for line B, indicating that line A mediated rescue with reduced penetrance. However, the fact that two independent transgene integrations mediated genetic rescue provides evidence that rescue was achieved through the actions of the inserted DNA and was not an artifact of the integration site. Because the penetrance of line-A mediated rescue was low, and lines C, D and E did not rescue, we hypothesized that these lines expressed either defective transcripts, or inappropriate levels, of BRCA1 as compared to line-B. To look at this more closely, we isolated protein from tissues of several TgN´BRCA1 lines and examined the expression of human BRCA1 protein.
Human BRCA1 protein, is expressed in TgN´BRCA1 GEN transgenic mice and responds to ionizing radiation Proteins extracted from the testis were analysed by immuno-precipitation followed by immuno-blotting with species-speci®c anti-human BRCA1 antibodies (Figure 3a) . Testis is a site of signi®cant BRCA1 expression (Lane et al., 1995; Scully et al., 1997b) due to a presumed role for the protein in homologous strand exchange (Snouwaert et al., 1999; Zabludo et al., 1996) . Antibodies were the generous gift of Drs C Wilson and D Slamon (UCLA School of Medicine, Los Angeles, CA, USA) and have been described elsewhere (Wilson et al., 1997 (Wilson et al., , 1999 . None of the antibodies used in this experiment cross-reacted with extracts derived from mice. Detection of protein required immuno-precipitation from 500 mg of tissue due to low levels of protein expression (preliminary data not shown). The protein migrated as a doublet at 230 ± 240 kD with a smaller band (approximately 98 kD) visible in transgenic lines A and B. Although the intensity varied considerably between individual lines, the 230 ± 240 kD doublet was detected in all four TgN´BRCA1 transgenic lines tested (Figure 3a) . Lines C and D expressed the 230 ± 240 kD BRCA1 doublet at relatively low levels compared to lines A and B. This may represent a rationale for the inability of lines C and D to mediate rescue (Table 1) . Line A displayed an additional band migrating somewhat below the 230 ± 240 kD doublet. The signi®cance of the additional band in line A extracts is not clear, but might contribute, in part, to the dierence in rescue activity between lines A and B. Other tissues were tested as well with similar results, but protein expression levels were generally much lower and detection less reproducible. The expression of full-length protein from four of ®ve transgenic lines provides compelling evidence that pronuclear injection is a reliable mechanism for introducing large fragments of chromosome 17 for functional analysis in mice. . NP40 extracts (500 mg total protein) were prepared as described (Scully et al., 1997a) and subjected to immuno-precipitation with a rabbit anti-human BRCA1 polyclonal antibody (115), followed by SDS ± PAGE and immuno-blotting of precipitated proteins with an anti-human BRCA1 monoclonal antibody (SD118). Small arrows indicate immuno-reactive species in the TgN´BRCA1-B extract which correspond to bands identi®ed on extracts of human cells (not shown). The arrowhead identi®es a unique band observed only in transgenic line A. The size markers indicate the migration (relative kD) of size standards included on the gel. (b) Testicular tissue from transgenic line B was placed in tissue culture media and exposed to the indicated dosages of ionizingirradiation (IR) calibrated in Gray (0.1 or 5 Gy). Immunoprecipitates were prepared as above. Labeled proteins were visualized with HRP-labeled rabbit anti-mouse IgG followed by a chemiluminescence reaction (Pierce Chemical, Rockford, IL, USA) BRCA1 protein has been demonstrated to respond to DNA damaging agents by increased phosphorylation and movement out of nuclear dot structures Gowen et al., 1998; Scully et al., 1997a) . To test whether proteins expressed from the TgN´BRCA1-B transgene respond to DNA damaging agents, we isolated fresh tissues and exposed them to ionizing radiation for various time periods. Tissues were then cultured for 1 h at 378C. Proteins were extracted as described above. As demonstrated for testicular tissue, the 230 ± 240 kD BRCA1 doublet became more pronounced following exposure to gamma-irradiation (Figure 3b) . These results are consistent with a rapid increase in stability of the protein following radiation exposure as has been reported for BRCA1 in human tissue culture cell lines (Scully et al., 1997a) . The results also indicate that the human BRCA1 protein can interact functionally with the DNA damage response machinery in murine tissues.
Human BRCA1 transcripts are differentially expressed in TgN´BRCA1 GEN transgenic mice and mirror the pattern of endogenous Brca1 transcription
We developed a multiplex RNase protection assay (mRPA) that allowed simultaneous measurement of transcripts originating from mouse Brca1, the human BRCA1 transgene, and L32, an ubiquitously expressed ribosomal subunit protein (Figure 4) . The three riboprobes were mixed (30 : 30 : 1 ratio) and hybridized to various RNA extracts. As shown in Figure 4b mRPA detected only human transcripts in extracts from a human breast cell line (MCF7: lane 3) and only mouse transcripts in a mouse breast cell line (NuMG; lane 4). When the same RNA samples were mixed, both human and mouse transcripts were distinguishable (Figure 4b, lane 5) .
When the mRPA assay was used to measure transcripts in tissues from TgN´BRCA1-B transgenic animals, human BRCA1 mRNA was observed to parallel that of the mouse Brca1 transcript ( Figure  4c ). RNA isolated from thymus, breast, spleen, kidney and testis all showed signi®cant expression of both human and mouse BRCA1 genes (Figure 4) , while expression was low in muscle (Figure 4c, lane 3) . Interestingly, human BRCA1 transcripts were expressed in a 1 : 1 ratio with mouse Brca1 in male tissues (Figure 4c, lanes 6 ± 7) , while the human transcript was always more elevated in female tissues; approximately 1.8 : 1 in mammary gland (Figure 4c , lane 2). While it was beyond the scope of this study to pursue the potential role of sex steroids in the regulation of BRCA1, it is worth noting that the human BRCA1 gene contains a putative estrogen response element (Xu et al., 1997) which appears to be absent from the mouse promoter. TgN´BRCA1-B transgenic animals could therefore play a role in the study of similarities and dierences in the regulation of mouse and human BRCA1 genes.
Discussion
BRCA1 has been implicated in a variety of biological settings, including double-strand break repair and homologous recombination in mitotic cells (Cressman et al., 1999a; Snouwaert et al., 1999) , and DNA strand exchange in meiotic cell division Cressman et al., 1999a; Scully et al., 1997b; Zabludo et al., 1996) . Depending on the severity of the deletion, murine embryos lacking Brca1 die between 7.5 and 11 days of development due to accumulated DNA defects . We have shown that a fragment of human chromosome 17, containing a wild-type human BRCA1 allele, is capable of supporting development and a full array of adult functions in Brca1 7/7 de®cient mice. The observation that rescued mice live a full lifespan and rear normal litters, provides evidence that the human gene product is capable of complementing the absence of the mouse gene in both meiotic and mitotic cells.
Prior to generation of the TgN´BRCA1 GEN transgenic lines, we conducted experiments in which a series of heterologous promoters were used to direct BRCA1 in transgenic animals. The failure of these promoter-BRCA1 constructs to support development indicates that overexpressed, or mis-expressed, BRCA1 blocks development. This result was anticipated, in part, because of studies which demonstrate very low levels of BRCA1 expression in normal cells, and other studies that show cellular growth-arrest or apoptosis in many cell lines which overexpress BRCA1 (Shao et al., 1996; Wilson et al., 1997; Zhang et al., 1998) . When we transfected mammary cell lines with BRCA1 cDNAs linked to BRCA1 promoter sequences, we did not observe apoptosis or cellular arrest (T Lane and E Solomon, preliminary observations). These results support the need to better understand BRCA1 (2), muscle (3), spleen (4 and 6), thymus (5) and testis (7). Lanes 1 ± 5 represent tissues from female, and lanes 6 ± 7 from male, FVB/N;TgN´BRCA1-B mice. For both b and c, an L32 riboprobe is added to each reaction to show equivalence of RNA regulatory domains and suggest due caution in interpreting experiments which assess phenotypes of BRCA1 overproducing cells.
Over 140 distinct BRCA1 mutations have been identi®ed in breast and ovarian cancer-prone families worldwide (BIC, 1999) . In addition to inherited mutations, other means of regulating BRCA1 function may be important in sporadic tumors. The gene is down-regulated at the transcriptional level in sporadic cancer (Catteau et al., 1999; Mancini et al., 1998; Wilson et al., 1999) and the BRCA1 protein becomes mislocalized following infection with certain transforming viruses (Maul et al., 1998) . There are currently no models which allow testing for the consequences of individual mutations in the human BRCA1 gene in an intact animal system. By creating lines of mice that express human BRCA1, assessment of interactions with other transforming pathways and analysis of speci®c mutations can be greatly accelerated.
Materials and methods
Mouse strains and nomenclature FVB/N (Taconic, Germantown, NY, USA) is an inbred strain with characteristics that include large pronuclei amenable for microinjection, good parental care, and large litter size. Some of the mice described in this report were originally created on strain 129
SvEv but were then backcrossed into FVB/N to create FVB/N congenic strains as described below. TgN´BRCA1 GEN (abbreviated TgN´BRCA1) is a trangenic line generated in FVB/N carrying a 140 kb genomic fragment of the human BRCA1 locus. A targeted hypomorphic allele of Brca1 (the mouse BRCA1 locus) was generated as described below (Brca1 DexllSA ). Brca1 +/7 heterozygotes carry one copy, while Brca1 7/7 animals carry two copies, of the Brca1
DexllSA allele.
Constructs used to create specific transgenic mice
Two transgenic lines are described in this paper:(i) For generation of TgN´BRCA1 GEN , PAC103014 (Brown et al., 1995) was digested with NotI and gel puri®ed by pulse-®eld electrophoresis. Prior to microinjection into pronuclei of onecell FVB/N embryos, the 140 kb insert was electroeluted, concentrated by precipitation, and dialyzed against PIPES injection buer (10 mM PIPES pH 7.0, 0.15 M KCl, 5 mM NaCl) supplemented with 70 mM spermidine and 30 mM spermine; (ii) A hypomorphic allele of murine Brca1 (Brca1 DexllSA ) was generated by introducing the neomycin resistance gene in lieu of the endogenous splice acceptor for exon 11 of the murine Brca1 gene through homologous recombination in 129
SvEv derived TC-1 embryonic stem cells. The targeting vector created in pPNT (Tybulewicz et al., 1991 ) is identical to that described by Shen et al. (1998) , while the ES cells are derived from an independent transfection (C Deng and P Leder, unpublished). Chimeric founder animals were mated to FVB/N females and were backcrossed for 12 generations into FVB/N to create Brca1
DexllSA /FVB . All targeted mice used in the present study represent Brca1
DexllSA /FVB animals. Brca1
DexllSA carriers are denoted as Brca1 +/7 or Brca1 7/7 depending on the number of wild-type alleles present.
DNA isolation and Southern analysis
DNA was isolated from tails (1 cm), digested with EcoRI, resolved on 0.8% agarose/TAE gels, and transferred to nylon membranes, as described (Lane and Leder, 1997 Images were recorded on pre-¯ashed X-ray ®lm (Hyper®lm-MP, Amersham, Arlington Heights, IL, USA).
Antibodies and immuno-precipitation analysis
The anti-BRCA1 antisera used have been characterized extensively as described (Wilson et al., 1997 (Wilson et al., , 1999 . 115 is a rabbit polyclonal antibody useful for immuno-precipitation and SD118 is a mouse monoclonal antibody useful for immuno-blot analysis. Immuno-precipitations from tissue extracts were performed as follows. Tissues were extracted in RIPA buer: 150 mM NaCl, 1.0% NP40, 0.5% DOC, 0.1% SDS, 50 mM Tris-HCl (pH 8.0). The following inhibitors were added just before use: 0.25 mM EDTA, 0.1 mg/ml pepstatin A, 0.4 mM PMSF, 1 mM NaF, 1 mM NaVanadate, 1 mM NaPPi. Protein concentration was determined by Bradford Assay (Pierce, Rockford, IL, USA) and 500 mg aliquots were used for immuno-precipitation with 1 ml of antibody 115. Immuno-precipitates were dissolved in SDS-loading buer containing 4 mM DTT and run on either 8% or 3 ± 8% gradient minigels (NuPAGE, Novex, San Diego, CA, USA) following the manufacturer's guidelines. 8% gels were run for 6 h and 3 ± 8% gradient gels were run for 90 min at 150 mA/gel. Proteins were then transferred to Immobilon P membranes, blocked in MT buer (PBS containing 1% nonfat dried milk, 0.05% Tween-20), and incubated with primary antibody (SD118). Blots were developed with HRP-labeled anti-mouse IgG (Pierce) and a chemi-luminescence detection substrate (SuperSignal, Pierce). Labeled proteins were detected with X-Omat-AR X-ray ®lm, and regular X-Omatic intensifying screens (Kodak, Rochester, NY, USA).
RNase protection assays
RNA was isolated from tissues and cell lines by the acidphenol method (Trisol, Gibco/BRL, Grand Island, NY, USA) and 10 mg of total RNA were analysed by multiplex RNase protection assays (mRPA). Riboprobe vectors protected a 367 bp fragment of human BRCA1 cDNA, a 384 bp fragment of mouse Brca1 cDNA (nts) and an 112 bp fragment of mouse L32. cDNA sequences were introduced into pBSII-KS (Stratagene, La Jolla, CA, USA) and riboprobes were synthesized from linearized templates using T7 RNA polymerase in the presence of [ 32 P]UTP. Equal molar amounts of the two BRCA1 riboprobes were mixed with 10-fold less of the L32 probe before hybridization with RNA at 568C following the manufacturer's speci®cations (RPA kit, Pharmingen, San Diego, CA, USA). Mixtures were then treated with RNase and precipitated. Protected fragments were separated on 6% UREA ± PAGE sequencing gels. Labeled fragments were identi®ed by exposure to phosphoimager screens (Storm 860, Molecular Dynamics, Sunnyvale, CA, USA). Band intensities were normalized to the L32 signal.
Cells, tissue culture and g-radiation
All cells and tissues were maintained in complete medium containing DME medium (GIBCO Laboratories, Grand Island, NY, USA), 10% by volume FCS, 250 mg/ml amphotericin, 100 U/ml penicillin G and 100 U/ml strepto-mycin sulfate. For DNA damage studies, mouse tissues were harvested in serum-free medium and dissected into 3 mm fragments. Fragments were then washed by brief centrifugation and resuspended in serum-free medium prior to brief exposure to gamma-irradiation using a calibrated [ 137 Cs] source (maintained by the UCLA School of Medicine). Dosages were 0, 0.1 or 5 Gray (Gy) as reported in previous studies of human breast cell lines (Abbott et al., 1999; Scully et al., 1997a) . Tissues were then rinsed, transferred to complete medium, and incubated with agitation in a tissue culture incubator, 378C, 5% CO 3 . After 1 h, tissues were rinsed with serum-free media and extracted for protein analysis.
